Delving into the Latest Updates on Elecoglipron with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GLP-1 agonist (Eccogene), AZD5004, ECC 5004

+ [3]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseUrogenital DiseasesCardiovascular Diseases

Active Indication

Renal InsufficiencyHeart failure with mid range ejection fractionHeart failure with normal ejection fraction+ [7]

Inactive Indication-

Originator Organization

Eccogene (Shanghai) Co., Ltd

Active Organization

AstraZeneca PLCAstraZeneca ABAstraZeneca Global R&D (China) Co., Ltd.

+ [1]

Inactive Organization-

License Organization

AstraZeneca PLC

Eccogene (Shanghai) Co., Ltd

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC48H46F2N10O5

InChIKeyJMKBTILBGROESC-QUWDGAPNSA-N

CAS Registry2758659-09-3

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.

Start Date24 Aug 2026

Sponsor / Collaborator

AstraZeneca PLC

NCT07775404

/ RecruitingPhase 3

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (EMBOLD-Asia)

The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

Start Date21 Aug 2026

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with Elecoglipron

Login to view more data

100 Translational Medicine associated with Elecoglipron

Login to view more data

100 Patents (Medical) associated with Elecoglipron

Login to view more data

5

Literatures (Medical) associated with Elecoglipron

01 Jun 2026·LANCET

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial

Article

Author: Maaske, Jill ; Aberle, Jens ; Aroda, Vanita R ; Ciudin, Andreea ; Zarzuela, Donna ; Davies, Melanie J ; Millegård, Marcus ; Shih, Judy L ; McCrimmon, Rory J ; Juan, Víctor López ; Sjostrand, Mikaela ; Rosenstock, Julio ; Eklund, Olof

BACKGROUND:

Elecoglipron is an oral, small molecule glucagon-like peptide (GLP)-1 receptor agonist currently in development for the management of type 2 diabetes. Elecoglipron is orally administered once daily with no food or fluid restrictions. SOLSTICE, a phase 2b study, evaluated the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with type 2 diabetes.

METHODS:

This phase 2b, randomised, double-blind, placebo-controlled trial was conducted in medical research centres and hospitals across nine countries, Canada, Germany, Hungary, Japan, Poland, Slovakia, Spain, the UK, and the USA. Sites were selected based on their capacity to fulfil protocol requirement, including, but not limited to, regulatory and ethics approvals, appropriate infrastructure and personnel, and access to the target patient population. Participants aged 18 years and older with a BMI of 23 kg/m² or higher and type 2 diabetes (glycated haemoglobin [HbA_1c] ≥7·0% to ≤10·5%, ≥6·5% to ≤10·5% in the USA) managed with diet and exercise alone or monotherapy with metformin or an SGLT2 inhibitor were enrolled. Participants were randomly assigned (3:5:3:5:3:3:6:4) via an interactive web response system to elecoglipron as oral once-daily tablets without dose escalation (5, 15, or 25 mg) or three different dose-escalation regimens, to target doses of 50 mg and 75 mg. The daily dose of 50 mg was evaluated using an every 2-week dose-escalation schedule, while 75 mg was assessed with every 2-week or every 4-week dose-escalation schedules. Participants could also be randomly assigned to placebo matched to each of the elecoglipron groups, or open-label oral semaglutide titrated to 14 mg once daily for 26 weeks. Participants, the treating physician, and the sponsor were masked to doses of elecoglipron or matched placebo, while semaglutide was open-label. The primary endpoint was percent change in HbA_1c from baseline to 26 weeks. Efficacy, safety, and tolerability were assessed in all participants who received at least one dose of trial treatment. The trial is registered with ClinicalTrials.gov (NCT06579105) and clinicaltrials.eu (2024-512562-34-00) and is completed.

FINDINGS:

From Oct 8, 2024, to June 6, 2025, 863 individuals were screened for study inclusion, 457 were excluded as they did not meet the inclusion criteria or met the exclusion criteria, 406 were enrolled and randomly assigned to one of the eight treatment groups, and 404 participants received at least one dose of trial treatment. Among those who received at least one dose of trial treatment, mean (SD) baseline characteristics were: age 58·4 years (10·7); HbA_1c of 7·9% (0·9); bodyweight of 99·8 kg (22·1); and BMI of 34·9 kg/m² (7·5). Of 404 participants, 168 (42%) of participants were female and 236 (58%) were male; 280 (69%) were White. At week 26, the mean change from baseline in HbA_1c ranged between -0·91% (95% CI -1·25 to -0·58; 5 mg elecoglipron) and -1·88% (-2·23 to -1·53; 75 mg elecoglipron with every 2-week dose-escalation step) compared with -0·15% (-0·42 to 0·12) with placebo. Adverse events were reported by 63% (24 of 38 in the 5 mg group and 39 of 62 in the 15 mg group) to 87% (33 of 38 in 75 mg every 4-week dose escalation) of participants across elecoglipron doses compared with 63% (45 of 71) in the placebo group. The most common adverse events were gastrointestinal, including nausea, constipation, diarrhoea, and vomiting.

INTERPRETATION:

Once-daily oral elecoglipron showed reductions in glycaemia and a safety and tolerability profile consistent with the GLP-1 receptor agonist class at a similar phase of development, supporting continued development with phase 3 trials for people living with type 2 diabetes.

FUNDING:

AstraZeneca.

01 Jun 2026·LANCET

Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial

Article

Author: Johansson, Peter A ; Pedersen, Sue D ; Aroda, Vanita R ; Malhotra, Sonali ; Morizzo, Erika ; Rosenstock, Julio ; Sjöström, C David ; Capehorn, Matthew ; Davies, Melanie J ; Rizi, Ehsan Parvaresh ; Grice, Daniel ; Andersson, Alf

BACKGROUND:

Elecoglipron (AZD5004) is an oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist administered once daily without food or fluid restriction, in development for weight management in people living with obesity or overweight and type 2 diabetes. We assessed the efficacy, safety, and tolerability of elecoglipron versus placebo in participants with obesity or overweight and at least one weight-related condition without diabetes.

METHODS:

In this double-blind, randomised, controlled, phase 2 dose-ranging study with a total treatment duration of 36 weeks, adult participants were recruited from medical research centres and hospitals in Australia, Canada, Germany, Japan, Taiwan, the UK, and the USA. Participants were aged 18 years or older living with obesity (BMI ≥30 kg/m²) or with overweight (BMI ≥27 kg/m²) with at least one weight-related condition and without type 2 diabetes. Eligible participants were randomly assigned in a 2:3:3:3:3:5 ratio to receive 5 mg, 15 mg, 50 mg, 75 mg (weekly titration), or 75 mg (every 2-week titration) of elecoglipron or matching placebo. Elecoglipron was administered as oral once-daily tablets without titration (5 mg and 15 mg) and as three different dose-titration regimens. The daily dose of 50 mg was evaluated using an every-4-weeks dose-escalation schedule, while 75 mg was assessed with weekly or every 2-week dose-escalation schedules. Participants, treating physicians, and sponsor were masked to the treatment allocation. The dual primary endpoints were percent change in bodyweight from baseline and the proportion of patients reaching at least 5% weight loss at week 26. Safety and tolerability were assessed in all participants who received at least one dose of study treatment. This trial is registered at ClinicalTrials.gov (NCT06579092) and is completed.

FINDINGS:

From Oct 8, 2024, to Feb 18, 2025, 472 individuals were screened for potential study inclusion, 162 did not meet the inclusion criteria, and 310 participants were randomly assigned to the varied elecoglipron groups or placebo. 288 participants (93%) completed the study and 231 (75%) completed the assigned treatment. The mean age of participants was 48·4 years (SD 13·7), 225 (73%) were female, 85 (27%) were male, their mean bodyweight was 106·9 kg (SD 24·1), and their mean BMI was 38·2 kg/m² (SD 7·2). At week 26, the estimated mean change from baseline in bodyweight was between -2·6% (5 mg elecoglipron), and -10·5% (75 mg with weekly titration steps) compared with -0·6% with placebo. The estimated proportion of participants reaching weight reductions of at least 5% at week 26 was 40·4-88·8% with elecoglipron versus 15·6% with placebo. Adverse events were reported by 84% (27 of 32) to 98% (48 of 49) of participants across elecoglipron doses compared with 84% (68 of 81) in the placebo group, the most common being nausea, constipation, diarrhoea, headache, and vomiting.

INTERPRETATION:

Daily oral elecoglipron demonstrated clinically meaningful weight reductions and a safety and tolerability profile consistent with the GLP-1 receptor agonist class in this phase 2 dose-ranging study, supporting phase 3 investigation in people living with obesity or overweight.

FUNDING:

AstraZeneca.

01 Feb 2026·WIENER MEDIZINISCHE WOCHENSCHRIFT

Treatment outcomes and safety profile of SGLT2 inhibitors versus GLP-1 agonists in type 2 diabetes mellitus

Review

Author: Sahoo, Biswa Mohan ; Ur Rehman, Zia ; Mahapatra, Manoj Kumar ; Alam, Aftab ; Imran, Mohd

PURPOSE:

Several pharmacotherapies are available to treat type 2 diabetes mellitus (T2DM) among which sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide 1 (GLP-1) receptor agonists are significant. The current systematic review aims to critically evaluate various clinical outcomes and safety profile of SGLT2is in comparison to GLP‑1 receptor agonists for the management of T2DM utilizing real-world clinical data.

METHODS:

A total of 22,100 research articles were extracted from several electronic databases including EMBASE, PubMed, Clinicaltrials.gov, and Cochrane Library from January 2010 to September 2024. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to maintain consistency and transparency in research. To obtain insights from the real-world clinical data, observational studies were used for this review, excluding , randomized controlled trials.

RESULTS:

The pooled analysis showed that risk ratio (RR) of heart failure and MACE (major cardiovascular events) or revascularization, and odds ratio (OR) of renal outcomes were slightly higher among SGLT2is (experimental) as compared to GLP‑1 agonist (control). In addition, the pooled analysis of hypoglycemic events and all-cause mortalities favored SGLT2is as compared to GLP‑1 agonist.

CONCLUSION:

SGLT2is appear to be more effective in lowering hospitalization for heart failure; GLP‑1 medication appears to be safer and more successful in treating MACE and improving renal outcomes. Occurrence of hypoglycemic events and the rate of all-cause mortality were found to be low in the SGLT2is group, which supported the clinical implication of SGLT2is.

67

News (Medical) associated with Elecoglipron

28 Sep 2026

·www.biospace.com

Eccogene Receives $50 Million Milestone Payment from AstraZeneca Following Initiation of Global Phase 3 Program for Elecoglipron (AZD5004/ECC5004)

Elecoglipron is an investigational oral small molecule GLP-1 receptor agonist discovered by Eccogene and licensed to AstraZeneca outside Greater China in November 2023. Eccogene has earned $295 million to date under its collaboration with AstraZeneca and remains eligible to receive future milestones as well as royalty payments. BOSTON & SHANGHAI--(BUSINESS WIRE)-- Eccogene , a global clinical-stage biotechnology company developing therapies for cardiometabolic diseases and inflammatory disorders, today announced that it has received a $50 million milestone payment from AstraZeneca. The milestone payment was triggered by the initiation of the global Phase 3 clinical program of elecoglipron (AZD5004/ECC5004). Elecoglipron is an investigational, once-daily, oral small molecule GLP-1 receptor agonist for the treatment of cardiometabolic diseases. The elecoglipron Phase 3 program includes the Embold Phase III trials which will evaluate elecoglipron as treatment for people with obesity or overweight, with and without type 2 diabetes. The Eluminate Phase III trials will evaluate elecoglipron, as monotherapy and in combination with dapagliflozin, as treatment for people with type 2 diabetes. Two additional indication-seeking outcome trials (Elevate) will evaluate elecoglipron as treatment for people with heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF), and chronic kidney disease (CKD), on the background of dapagliflozin plus other standard of care. The initiation of the global Phase 3 program follows positive topline results from the Phase 2b VISTA and SOLSTICE trials, which demonstrated an 11.8% weight loss at 36 weeks in adults with obesity or overweight (with at least one weight-related comorbidity) and a 1.9% HbA1c reduction at 26 weeks in adults with type 2 diabetes, respectively. These results were presented at the American Diabetes Association 2026 Scientific Sessions in New Orleans and simultaneously published in The Lancet ( VISTA , SOLSTICE ). “Elecoglipron entering Phase 3 is the moment our team has been building toward since we first discovered this molecule,” said Jingye Zhou, Ph.D., Chief Executive Officer of Eccogene. “Elecoglipron was born out of our internal research, and its progression into an extensive global Phase 3 program with the strong leadership of AstraZeneca, is a direct result of that work and a meaningful step toward new oral options for people living with obesity/overweight, type 2 diabetes, heart failure and CKD.” Leveraging its translational research workflow and deep understanding of metabolic disease pathways, Eccogene is advancing a pipeline of next-generation therapeutics that can be used alone or in combination with GLP-1 receptor agonists. In addition to elecoglipron, the Company’s pipeline includes clinical-stage programs targeting THR-β and SSAO, as well as preclinical programs targeting GIPR, AmylinR, and others. About Elecoglipron Elecoglipron is an investigational oral, small-molecule GLP-1 receptor agonist discovered by Eccogene. It is designed to offer a convenient once-daily dosing regimen with no food- or water-related restrictions, which may help support patient adherence and broaden access. In November 2023, Eccogene entered into an exclusive licensing agreement with AstraZeneca for elecoglipron outside Greater China, while retaining co-development and co-commercialization rights within Greater China. Under the agreement, Eccogene received an upfront payment of $185 million and is eligible for up to $1.825 billion in total clinical, regulatory, and commercial milestones (inclusive of the $110 million milestone payments already received), as well as royalty payments. About Eccogene Eccogene is a global clinical-stage biotechnology company established in 2018 with an integrated pipeline comprising three clinical-stage drug candidates and multiple preclinical programs. The company aims to become a global leader in developing therapies for cardiometabolic diseases and inflammatory disorders. For more information, please visit or follow the company on LinkedIn . Forward-Looking Statements This press release may contain forward-looking statements that reflect the Company's current expectations, beliefs, plans and projections. These statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those anticipated. Such factors include, without limitation, changes in market conditions, regulatory developments, competitive landscape and general economic conditions. Save as required by applicable law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts investors@eccogene.com

Phase 2Phase 3License out/inClinical Result

17 Aug 2026

·www.biospace.com

AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow

iStock, Nuthawut Somsuk AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma. AstraZeneca will discontinue a Phase 3 study for its investigational bispecific antibody volrustomig in non-small cell lung cancer following disappointing interim data. The pharma was testing volrustomig in the late-stage eVOLVE-Lung02 trial in combination with chemotherapy as a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression levels lower than 50%. The study compared the volrustomig regimen against Merck’s Keytruda plus chemotherapy. A planned review of the trial data showed that volrustomig was unlikely to hit either of the study’s primary endpoints of progression-free survival or overall survival, according to a Monday morning release . Thus, the independent data panel recommended the study’s termination. AstraZeneca did not provide specific data in its release. The pharma is “disappointed” with the results, Susan Galbraith, executive vice president of Oncology Hematology R&D, said in a prepared statement, adding that the company “will learn from this trial.” AstraZeneca will continue its other Phase 3 volrustomig studies as planned in mesothelioma, cervical cancer, and head and neck squamous cell carcinoma. The latest blow continues what has been a rough few months for AstraZeneca in the clinic. Most notably, the pharma last month announced that its antisense therapy Wainua, which it shares with Ionis Pharmaceuticals, failed to show significant cardiovascular benefit in a Phase 3 study transthyretin amyloidosis-cardiomyopathy (ATTR-CM) study. The stumble sent waves across the ATTR-CM space, casting doubt on the silencer class of therapies—which work by suppressing transthyretin expression—and giving a boost to stabilizers, which prevent the protein from misfolding, a crucial pathogenic step. Cardiovascular disease AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics. July 10, 2026 · 3 min read · Tristan Manalac Read more Aside from Wainua, AstraZeneca also revealed in July that its rare disease drug Ultomiris failed to achieve statistically significant event-free survival in the Phase 3 ALXN1210-TMA-313 trial, which enrolled patients 12 years and older with thrombotic microangiopathy who had received hematopoietic stem cell transplant. That same day, during its second quarter earnings report , the pharma disclosed some other clinical disappointments, including in the Phase 3 CLARITY-Gastric01 trial, where its antibody-drug conjugate sonesitatug vedotin failed to significantly boost progression-free survival in the overall study population of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The asset did improve overall survival in these patients. Earnings AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure AstraZeneca remains “very much on track” to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said during the company’s Q2 earnings presentation on Monday. July 27, 2026 · 3 min read · Tristan Manalac Read more Even in the case of a clinical win, AstraZeneca can’t seem to catch a break. In June, its investigational GLP-1 pill elecoglipron demonstrated a nearly 10% weight reduction at 25 weeks as compared with placebo. At 36 weeks, placebo-adjusted weight loss increased to 11.5%. While BMO Capital Markets at the time said these data pointed to elecoglipron’s “promising efficacy,” the firm added that the results were otherwise “relatively underwhelming,” especially compared with other drugs in development—particularly Structure Therapeutics’ aleniglipron, which showed a 15.3% placebo-adjusted weight reduction at 36 weeks . Editor’s note (Aug. 18): The headline of this story was changed to more accurately reflect AstraZeneca’s recent clinical developments.

Phase 3Clinical Result

17 Aug 2026

·www.biospace.com

AstraZeneca pulls plug on late-stage lung cancer trial, extending losing streak

iStock, Nuthawut Somsuk AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma. AstraZeneca will discontinue a Phase 3 study for its investigational bispecific antibody volrustomig in non-small cell lung cancer following disappointing interim data. The pharma was testing volrustomig in the late-stage eVOLVE-Lung02 trial in combination with chemotherapy as a first-line treatment option for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression levels lower than 50%. The study compared the volrustomig regimen against Merck’s Keytruda plus chemotherapy. A planned review of the trial data showed that volrustomig was unlikely to hit either of the study’s primary endpoints of progression-free survival or overall survival, according to a Monday morning release . Thus, the independent data panel recommended the study’s termination. AstraZeneca did not provide specific data in its release. The pharma is “disappointed” with the results, Susan Galbraith, executive vice president of Oncology Hematology R&D, said in a prepared statement, adding that the company “will learn from this trial.” AstraZeneca will continue its other Phase 3 volrustomig studies as planned in mesothelioma, cervical cancer, and head and neck squamous cell carcinoma. The latest blow continues what has been a rough few months for AstraZeneca in the clinic. Most notably, the pharma last month announced that its antisense therapy Wainua, which it shares with Ionis Pharmaceuticals, failed to show significant cardiovascular benefit in a Phase 3 study transthyretin amyloidosis-cardiomyopathy (ATTR-CM) study. The stumble sent waves across the ATTR-CM space, casting doubt on the silencer class of therapies—which work by suppressing transthyretin expression—and giving a boost to stabilizers, which prevent the protein from misfolding, a crucial pathogenic step. Cardiovascular disease AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics. July 10, 2026 · 3 min read · Tristan Manalac Read more Aside from Wainua, AstraZeneca also revealed in July that its rare disease drug Ultomiris failed to achieve statistically significant event-free survival in the Phase 3 ALXN1210-TMA-313 trial, which enrolled patients 12 years and older with thrombotic microangiopathy who had received hematopoietic stem cell transplant. That same day, during its second quarter earnings report , the pharma disclosed some other clinical disappointments, including in the Phase 3 CLARITY-Gastric01 trial, where its antibody-drug conjugate sonesitatug vedotin failed to significantly boost progression-free survival in the overall study population of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The asset did improve overall survival in these patients. Earnings AstraZeneca has no plans to ramp up dealmaking in wake of Wainua failure AstraZeneca remains “very much on track” to hit its 2030 goal of reaching $80 billion in revenue despite the recent late-stage failure of Wainua in ATTR-cardiomyopathy, CEO Pascal Soriot said during the company’s Q2 earnings presentation on Monday. July 27, 2026 · 3 min read · Tristan Manalac Read more Even in the case of a clinical win, AstraZeneca can’t seem to catch a break. In June, its investigational GLP-1 pill elecoglipron demonstrated a nearly 10% weight reduction at 25 weeks as compared with placebo. At 36 weeks, placebo-adjusted weight loss increased to 11.5%. While BMO Capital Markets at the time said these data pointed to elecoglipron’s “promising efficacy,” the firm added that the results were otherwise “relatively underwhelming,” especially compared with other drugs in development—particularly Structure Therapeutics’ aleniglipron, which showed a 15.3% placebo-adjusted weight reduction at 36 weeks .

Phase 3Clinical Result

100 Deals associated with Elecoglipron

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D13345	-	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Renal Insufficiency	Phase 3	United States	AstraZeneca Global R&D (China) Co., Ltd.	10 Sep 2026
Renal Insufficiency	Phase 3	United States	AstraZeneca AB	10 Sep 2026
Renal Insufficiency	Phase 3	China	AstraZeneca AB	10 Sep 2026
Renal Insufficiency	Phase 3	China	AstraZeneca Global R&D (China) Co., Ltd.	10 Sep 2026
Renal Insufficiency	Phase 3	Japan	AstraZeneca AB	10 Sep 2026
Renal Insufficiency	Phase 3	Japan	AstraZeneca Global R&D (China) Co., Ltd.	10 Sep 2026
Renal Insufficiency	Phase 3	Bulgaria	AstraZeneca Global R&D (China) Co., Ltd.	10 Sep 2026
Renal Insufficiency	Phase 3	Bulgaria	AstraZeneca AB	10 Sep 2026
Renal Insufficiency	Phase 3	Denmark	AstraZeneca Global R&D (China) Co., Ltd.	10 Sep 2026
Renal Insufficiency	Phase 3	Denmark	AstraZeneca AB	10 Sep 2026

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06579092 (VISTA, Pubmed \| Lancet)	Phase 2	Overweight \| Obesity	310	Elecoglipron 5 mg	moogdutipq(pgpscyakoc) = xonjvohzdp tqpuocmzpz (olwxtvuyaa )	Positive	01 Jun 2026
				Elecoglipron 15 mg	moogdutipq(pgpscyakoc) = yrdurjegeb tqpuocmzpz (olwxtvuyaa )
NCT05654831 (ECC5004/AZD5004, Pubmed \| Diabetes Obes Metab)	Phase 1	-	-	ECC5004/AZD5004	gwcpzeasza(rwxumfokoa) = Dose‐dependent body weight changes compared to control were seen in the 9‐month NHP toxicity study iypucfmnrf (snsewklpjq ) View more	Positive	01 Feb 2025
NCT05654831 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2	-	ECC5004/AZD5004	cxmcojbfvb(sormmnojyk) = None ettrmchckf (vmkquvxjpp ) View more	Positive	04 Nov 2024
NCT05654831 (NEWS) Manual	Phase 1	Diabetes Mellitus, Type 2	-	AZD5004 50mg	dwapcmnlqi(uhjlmqoaug): Difference = -76.6 mg/dL View more	Positive	04 Nov 2024
				Placebo